tiprankstipranks
Trending News
More News >
Agronomics Limited (GB:ANIC)
LSE:ANIC

Agronomics (ANIC) AI Stock Analysis

Compare
120 Followers

Top Page

GB:ANIC

Agronomics

(LSE:ANIC)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 5.2)
,
Neutral 44 (OpenAI - 5.2)
,
Neutral 44 (OpenAI - 5.2)
Rating:44Neutral
Price Target:
7.00 p
â–²(9.37% Upside)
Action:ReiteratedDate:01/04/26
The score is weighed down primarily by weak financial performance (recent losses and persistently negative cash flow), with technicals also bearish (price below key moving averages and negative MACD). Valuation is additionally constrained by a negative P/E driven by losses and no dividend data to offset risk; the main positive is the debt-free balance sheet, though equity has been eroding.
Positive Factors
Debt-free balance sheet
A zero-debt capital structure materially reduces financial risk and interest burden, giving Agronomics durability through long development cycles. This provides optionality to fund follow-on investments or survive cash burn without immediate leveraged pressure, supporting long-term portfolio strategy.
Targeted sector exposure
Agronomics' focused investment mandate in cellular agriculture and cultivated meat aligns it with structural sustainability trends. As a listed investor it gains diversified exposure to multiple early-stage decimals of innovation and multiple exit/NAV pathways, a durable model if commercialization progress continues.
Prior positive returns history
Historical profitability in 2022–2023 demonstrates the portfolio has generated meaningful realized or valuation gains in the past, indicating the manager can identify value. That track record supports the structural thesis that future successful exits could restore NAV and investor returns over a multi-quarter horizon.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow erodes financial flexibility and forces dependence on capital raises or asset sales to fund operations and follow-ons. Over months this increases dilution risk, constrains ability to support portfolio companies through long commercialization timelines, and raises funding execution risk.
Earnings deterioration
A sharp swing from previous profits to material losses and falling revenue signals valuation write-downs or poor exit timing in the portfolio. This deterioration reduces NAV resilience and makes it harder to finance growth without diluting shareholders, impairing long-term return potential unless reversals occur.
Equity erosion & negative ROE
Material declines in equity and negative returns on equity indicate capital destruction at the portfolio level. This reduces the company’s buffer to absorb further losses, limits capacity for follow-on investments, and raises structural funding and governance challenges over the medium term.

Agronomics (ANIC) vs. iShares MSCI United Kingdom ETF (EWC)

Agronomics Business Overview & Revenue Model

Company DescriptionAgronomics Limited is a principal investment firm specializing in investments in funds, equity and equity related products. The firm invests in quoted and unquoted companies. It prefers to invest in the alternative proteins company with a focus on cellular agriculture, nascent industry of modern foods, biopharma sector and will establish a portfolio of investments in biotechnology and biopharmaceutical companies. The firm may also invest in shares of collective investment schemes with exposure to the biopharma sector and in long-term equity anticipation securities the underlying securities of which will be based on biopharma sector securities and/or indices relating to the biopharma Sector. It may invest in biopharma sector debt, where investments shall not exceed 15 per cent of the net asset value of the company. Agronomics Limited was founded on May 3, 2011 and is based in Ramsey, Isle of Man.
How the Company Makes MoneyAgronomics primarily makes money through investment returns from its portfolio rather than through operating revenue from selling products or services. Its main potential earnings drivers are: (1) Realized gains on exits: selling equity stakes in portfolio companies during liquidity events such as trade sales, mergers and acquisitions, or initial public offerings; gains may also be realized through partial secondary sales of holdings. (2) Unrealized gains reflected in net asset value (NAV): increases in the fair value of its equity and equity-linked holdings can raise reported NAV, although these valuation gains are not cash income unless and until an investment is sold. (3) Investment income where applicable: if any holdings include instruments such as loans, convertible notes, preferred instruments with coupons/dividends, or other structured securities, Agronomics could earn interest or dividend income; specific amounts and materiality are not available here and therefore are null. (4) Capital raising and portfolio management: as a listed investment company, it may raise additional capital to fund new or follow-on investments; this supports growth of the asset base but is not itself operating revenue. Key factors influencing its ability to generate returns include the pace of commercialization and funding conditions in cellular agriculture, the valuation of private portfolio companies, and the timing and availability of exit opportunities. Specific significant partnerships contributing directly to earnings are null.

Agronomics Financial Statement Overview

Summary
Fundamentals are weak despite a low-risk capital structure. Income statement performance deteriorated sharply into large losses in 2024–2025, and cash flow is persistently negative (operating cash flow and free cash flow negative across all periods), implying the business has not been self-funding. The key offset is a debt-free balance sheet with a still-meaningful equity base, though equity has declined since 2023.
Income Statement
28
Negative
Earnings quality and consistency are weak. Results swung from strong profitability in 2022–2023 (positive net income) to sizable losses in 2024 and a deeper loss in 2025, alongside a sharp revenue decline in 2025. Margins are also noisy (including periods where revenue is negative), which reduces confidence in the underlying run-rate profitability.
Balance Sheet
70
Positive
The balance sheet is a clear relative strength: the company reports zero debt across periods and maintains a sizable equity base. However, equity has declined materially since 2023, and returns on equity turned meaningfully negative in 2024–2025, signaling value erosion despite the low leverage.
Cash Flow
22
Negative
Cash generation is a major concern. Operating cash flow and free cash flow are negative in every year shown, indicating the business has not been self-funding. While the cash burn improved significantly in 2025 versus 2024, free cash flow remains negative and does not consistently align with reported profitability in earlier years.
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue-11.92M-11.92M-8.34M29.70M440.32K10.67M
Gross Profit0.000.00-8.34M29.70M440.32K10.67M
EBITDA-10.05M-26.47M0.000.001.50M0.00
Net Income-16.18M-32.75M-10.99M22.37M8.36M1.02M
Balance Sheet
Total Assets140.21M124.67M157.44M170.20M146.40M101.65M
Cash, Cash Equivalents and Short-Term Investments2.15M124.62M12.24M169.87M146.30M101.21M
Total Debt0.000.000.000.000.000.00
Total Liabilities234.67K147.60K166.17K1.95M2.49M1.62M
Stockholders Equity139.97M124.52M157.27M168.26M143.91M100.03M
Cash Flow
Free Cash Flow-1.24M-1.12M-15.86M-23.67M-42.21M-12.17M
Operating Cash Flow-1.24M-1.12M-15.86M-23.67M-42.21M-12.17M
Investing Cash Flow2.28M1.59M892.00K10.02M-20.02M-11.21M
Financing Cash Flow0.001.71K1.68K1.01M31.25M71.82M

Agronomics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price6.40
Price Trends
50DMA
6.26
Positive
100DMA
6.65
Positive
200DMA
7.01
Negative
Market Momentum
MACD
0.15
Positive
RSI
52.26
Neutral
STOCH
51.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ANIC, the sentiment is Neutral. The current price of 6.4 is below the 20-day moving average (MA) of 6.76, above the 50-day MA of 6.26, and below the 200-day MA of 7.01, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 52.26 is Neutral, neither overbought nor oversold. The STOCH value of 51.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:ANIC.

Agronomics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
67
Neutral
£116.97M21.201.79%3.29%-9.37%―
63
Neutral
£785.81M2.308.81%―11.00%―
62
Neutral
£147.51M11.9817.51%17.93%-16.53%-44.15%
52
Neutral
£14.96M-2.82-16.69%―30.40%23.48%
50
Neutral
£450.55M8.097.16%――33.10%
44
Neutral
£70.79M1.56-12.24%――-600.00%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:ANIC
Agronomics
6.70
-0.90
-11.84%
GB:GROW
Molten Ventures
455.40
177.90
64.11%
GB:IPX
Impax Asset Management
121.80
-58.56
-32.47%
GB:IPO
IP Group plc
51.00
6.75
15.25%
GB:MERC
Mercia Asset Management
27.50
1.99
7.80%
GB:EMVC
NetScientific
53.50
12.50
30.49%

Agronomics Corporate Events

Other
Agronomics Chair Jim Mellon Lifts Stake to Nearly 16% With Fresh Share Purchases
Positive
Mar 12, 2026

Agronomics Limited has disclosed that its Executive Chair, Jim Mellon, has purchased a total of 3,308,995 additional ordinary shares in a series of market transactions between 6 and 12 March 2026. The shares were acquired at prices ranging from 6.6 pence to 7.0 pence per share, signalling continued confidence from the company’s top leadership.

Following these purchases, Mellon’s total holding, including closely associated entities, has risen to 165,775,997 ordinary shares, representing 15.69% of Agronomics’ voting rights. The increased stake consolidates his position as a major shareholder, which may be viewed by investors as a strong endorsement of the company’s clean food strategy and long‑term prospects.

The most recent analyst rating on (GB:ANIC) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and Strategy
Agronomics Chair Jim Mellon Increases Stake to Over 15%
Positive
Mar 4, 2026

Agronomics Limited has disclosed that its executive chair, Jim Mellon, along with his indirectly wholly owned vehicle Galloway Limited, has acquired a combined 575,785 ordinary shares in the company at a price of 6.8 pence per share over several transactions in late February and early March. Following these purchases, Mellon’s total interest, including associated entities, has risen to 162,467,002 ordinary shares, representing 15.38% of Agronomics’ voting rights, signalling a strengthened commitment from the company’s leading insider and potentially reinforcing investor confidence in its clean food strategy.

The most recent analyst rating on (GB:ANIC) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and Strategy
Agronomics Chair Jim Mellon Increases Stake with 990,000‑Share Purchase
Positive
Feb 25, 2026

Agronomics Limited has disclosed that Galloway Limited, an entity indirectly wholly owned by Executive Chair Jim Mellon, has acquired a total of 990,000 additional ordinary shares in the company over three consecutive trading days. The purchases, made at prices around 6.63 to 6.65 pence per share, increase Mellon’s aggregate holding to 161,891,217 ordinary shares, representing 15.32% of Agronomics’ voting rights.

The director dealing underscores a further vote of confidence from the company’s senior leadership in Agronomics’ clean food strategy and long‑term prospects. Mellon’s enlarged stake consolidates his influence over the company’s direction and may reassure shareholders about management’s alignment with investor interests as the business pursues growth in the emerging sustainable food market.

The most recent analyst rating on (GB:ANIC) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyRegulatory Filings and Compliance
Agronomics Chair Jim Mellon Increases Stake to Over 15%
Positive
Feb 20, 2026

Agronomics Limited has disclosed that Galloway Limited, an entity indirectly wholly owned by Executive Chair Jim Mellon, has acquired more than 1.28 million ordinary shares in the company over three consecutive trading days at around 6 pence per share. Following these purchases, Mellon’s total interest has risen to 160,901,217 ordinary shares, giving him 15.23% of Agronomics’ total voting rights and further aligning the chair’s position with that of other shareholders.

The increased stake by the executive chair underscores insider confidence in Agronomics’ strategy in the clean food sector and may be interpreted by investors as a positive signal about the company’s prospects. The transactions, disclosed under UK Market Abuse Regulation, reinforce transparency requirements for directors’ dealings and highlight the governance framework around significant shareholdings in AIM-listed companies.

The most recent analyst rating on (GB:ANIC) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Agronomics Swings to Profit as Clean Food Portfolio Gains Value
Positive
Feb 17, 2026

Agronomics reported a sharp turnaround to a net profit of £10 million for the six months to 31 December 2025, driven by £10.7 million of net investment gains and only modest operating costs. Net asset value per share rose 11.7% to 13.78 pence and total net assets increased to £140 million, although the shares continued to trade at a steep 55% discount to NAV, underlining persistent investor caution.

Portfolio value was buoyed by fair value gains in Blue Nalu and Liberation Bioindustries, foreign-exchange tailwinds and share-based deal structures, partially offset by a prior £11.9 million write-down of Meatable. Operationally, several holdings achieved important regulatory and commercial milestones, notably GRAS approvals for novel ingredients and capacity expansions, reinforcing Agronomics’ strategic positioning in alternative proteins despite a challenging funding environment for clean food start-ups.

Post period-end, Agronomics deepened its exposure to precision-fermented dairy by investing a further AU$3 million in All G through the issue of new shares at close to NAV. The company also continued to support later-stage portfolio names such as SuperMeat, EVERY Company and Blue Nalu via follow-on investments, indicating an active capital deployment strategy into companies it sees as best placed to scale.

The most recent analyst rating on (GB:ANIC) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyShareholder Meetings
Agronomics Wins Full Shareholder Backing at Annual General Meeting
Positive
Feb 13, 2026

Agronomics Limited announced that all resolutions proposed at its Annual General Meeting held on 13 February 2026 were duly passed. The approval of all AGM resolutions provides the company with shareholder backing for its current strategy and governance framework, reinforcing its position in the clean food sector and offering continuity for investors and other stakeholders.

This outcome signals stability in Agronomics Limited’s corporate direction, supporting ongoing initiatives in sustainable food technologies. With no contested items reported, the AGM results suggest broad shareholder alignment with the board’s plans as the company continues to advance its clean food investment agenda.

The most recent analyst rating on (GB:ANIC) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Agronomics Boosts Stake in Precision Fermentation Firm All G with AU$3 Million Note Investment
Positive
Jan 15, 2026

Agronomics has invested a further AU$3 million in Australian biotech All G, which uses precision fermentation to produce human and bovine milk proteins, notably animal‑free lactoferrin for applications in infant and clinical nutrition, functional foods, skincare and animal nutrition. The funding, made via a convertible note as part of a wider AU$10 million round and settled through the issue of 10,026,375 new Agronomics shares, will support All G’s commercial‑scale production, regulatory work and expansion in Asia and Europe after it secured pioneering approvals for recombinant bovine lactoferrin in China and self‑affirmed GRAS status in the US; post‑transaction, Agronomics’ total investment in All G rises to about £8.9 million and its own share capital increases to 1,056,575,208 shares, with potential implications for shareholder notifications under disclosure rules.

The most recent analyst rating on (GB:ANIC) stock is a Hold with a £6.00 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyFinancial DisclosuresShareholder Meetings
Agronomics Takes Heavy Write-Downs but Portfolio Wins Key Regulatory and Commercial Milestones
Negative
Dec 30, 2025

Agronomics reported a sharp decline in performance for the year to 30 June 2025, with net asset value per share falling 20% to 12.34 pence and a swing to a £32.7 million net operating loss, driven largely by £25.1 million of net investment losses, adverse foreign exchange movements and significant write-downs, including the full impairment of its £11.9 million stake in Meatable following that company’s voluntary liquidation. Total assets fell to £124.7 million and cash balances dropped to £3.6 million, underscoring tighter financial conditions even as the group continued to support key holdings such as Liberation Bioindustries and SuperMeat through follow-on funding.

Despite the financial hit, the portfolio achieved notable regulatory and commercial milestones that strengthen Agronomics’ strategic position in cellular agriculture, with Meatly securing first-in-world approvals and sales for cultivated pet food in the UK and Europe, Solar Foods listing in Finland and expanding partnerships with Ajinomoto, and All G gaining Chinese regulatory clearance for recombinant bovine lactoferrin. Additional progress included new manufacturing and offtake partnerships for Liberation Bioindustries, expanded collaboration for BlueNalu in European cultivated seafood, and multiple regulatory clearances for alternative proteins and specialty oils, suggesting that while sector funding has tightened and weaker players are being written off, leading assets in Agronomics’ portfolio are edging closer to commercial scale and diversified revenue streams. The company also set 13 February 2026 for its AGM, encouraging shareholders to exercise their voting rights by proxy and engage with management ahead of the meeting.

The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
Agronomics boosts BlueNalu stake with US$6.6m mix of equity and convertible notes
Positive
Dec 30, 2025

Agronomics has deepened its exposure to cultivated seafood pioneer BlueNalu with a US$6 million equity subscription in new preferred shares and a further US$600,000 investment in BlueNalu’s 2025 convertible promissory note round, taking its fully diluted stake to an expected 12.96%. The equity leg of the deal is being settled through the issuance of 30,643,003 new Agronomics ordinary shares at the company’s latest reported net asset value per share, while the CPNs, part of an approximately US$8 million round led by specialist food-tech investors, will convert into preferred stock on favourable terms upon a qualifying fundraise. The new Agronomics shares issued to BlueNalu are subject to a one-year lock-in and orderly market restrictions, and admission of the enlarged share capital to AIM is expected around 7 January 2026, implying modest dilution for existing shareholders but reinforcing Agronomics’ strategic bet on cell-cultivated seafood as BlueNalu advances regulatory engagement, commercial launch preparations for its cultivated bluefin tuna toro, and broader value-chain partnerships.

The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Agronomics Writes Off Meatable Stake as Cultivated Meat Venture Dissolves
Negative
Dec 19, 2025

Agronomics has announced that its portfolio company Meatable B.V. will be dissolved and all operating activities terminated after the cultivated meat business failed to secure continued funding from existing or new investors. The board and shareholders opted for an orderly wind-down under statutory liquidation procedures, leading Agronomics to write down its £11.9 million carrying value in Meatable to zero, crystallising the loss of its £7.9 million total investment, which represented about 8.1% of its net asset value as of 30 September 2025; despite the setback, the company stressed it remains focused on actively managing and supporting the rest of its portfolio with strong long-term growth prospects.

The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Business Operations and StrategyPrivate Placements and Financing
Agronomics Lifts Stake as Liberation Bioindustries Closes First Tranche of Series A1 Funding
Positive
Dec 19, 2025

Agronomics has strengthened its position in precision fermentation by announcing that portfolio company Liberation Bioindustries has closed the first tranche of its Series A1 equity round, supporting the completion of a 600,000-litre commercial-scale biomanufacturing facility in the US. The plant will produce bio-based proteins and other food ingredients for consumer goods and industrial manufacturers, underpinned by recent partnerships with Vivici to produce dairy protein Vivitein BLG at commercial volumes and with NEOM’s food company Topian to co-develop a fermentation facility in Saudi Arabia. As part of the round, Agronomics has converted all its convertible loan notes into Series A1 shares, increasing its holding from 6,834,147 to 16,538,437 shares, and now carries its total US$27 million investment in Liberation Bioindustries at US$46.8 million, equivalent to about 23% of its last reported net asset value; an affiliate, New Agrarian Company, will also invest US$2.5 million, underscoring Agronomics’ conviction that Liberation’s infrastructure will be a key asset in reshaping ingredient production and bolstering food and supply-chain security.

The most recent analyst rating on (GB:ANIC) stock is a Buy with a £15.90 price target. To see the full list of analyst forecasts on Agronomics stock, see the GB:ANIC Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 04, 2026